Management at Medtronic (MDT) Cautiously Optimistic End-Markets Stabilizing

Article Stock Quotes (1) Comments (0)

Recently analysts at UBS met with the Gary Ellis (CEO) and Jeff Warren (VP) at medical technology company Medtronic (NYSE: MDT). The executives were cautiously optimistic that underlying core end-markets are stabilizing, though visibility is imperfect, particularly in Spine.

Analysts said there was “reasonable plausibility” that guidance could be lifted next quarter if end-markets continue to cooperate.

Analyst also said that the Spine market looked like it was improving, and the ICD market was stabilizing.

UBS raises their price target on Medtronic to $48 from $46 and reiterated their Buy rating.

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $42.83 yesterday, with a 52 week range of $31.06-$43.18.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
• Dougherty & Co Raises PT on SodaStream (SODA) to $80
• UBS Raises PT on MEMC (WFR); Thinks Semi Sales Troughed in Q1

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?